Select a Region North America

Rare Diseases and Orphan Products Breakthrough Summit

Join EVERSANA™ at NORD’s 2022 Rare Diseases and Orphan Products Breakthrough Summit, the most important global rare disease and orphan products event October 17-18 in Washington, D.C.  Visit booth #306 or schedule a meeting with EVERSANA’s experts to learn how EVERSANA leads the way in simplifying complex rare disease patient journeys.   

EVERSANA’s Rare Disease Expertise  

With over 7,000 distinct rare and genetic diseases affecting 400+ million individuals, the average time to diagnosis still remains approximately 7 years. In response, EVERSANA has developed innovative, end-to-end strategies to assure patients are identified, diagnosed, onboarded and remain adherent to their treatment plans. 

Rare and orphan drug manufacturers are becoming increasingly aware that new models and new approaches are needed for a successful product launch. With experience in 25 disease states, EVERSANA™ COMPLETE Commercialization is uniquely positioned to remove friction in commercialization to enable an accelerated path to market introduction for critical therapies. Powered by artificial intelligence (AI), machine learning (ML) and Data & Analytics, our end-to-end model supplies predictive analytics to reach patients, improves access to therapy and facilitates positive outcomes.  

By leveraging data and AI capabilities of ACTICS by EVERSANA™ across the patient journey, EVERSANA can predict patient switching behaviors that impact adherence and engagement. This information also powers the optimization of our hub and affordability programs and deploys the “next best action” for each patient, leading to up to a 50% patient adherence improvement over a traditional hub program. 

EVERSANA’s patient services models simplify and expedite the patient journey. Our hub accelerates patient onboarding by supplying real time eligibility determination, self-enrollment with support options, ePa electronic benefit verification (eBV), (ePA), co-pay eligibility and e-prescribing. Our specialty pharmacy model connects patients, providers and payers to offer direct-to-patient dispensing and administration. In addition, data-driven patient profiling can determine customized outreach to provide education and deliver white-glove support to patients, driving brand loyalty and adherence. 

About NORD’s 2022 Rare Diseases and Orphan Products Breakthrough Summit 

Join fellow rare disease leaders from patient advocacy groups, government, industry, and academia for exclusive access to fresh insights, compelling connections, and expert resources.  

Schedule a time to meet with EVERSANA’s experts today!